Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IO Biotech, Inc. - Common Stock (NQ:IOBT)

1.380 +0.330 (+31.43%)
Streaming Delayed Price Updated: 3:31 PM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IO Biotech, Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
Top movers in Tuesday's session
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
These stocks are moving in today's after hours session
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. 
Via Chartmill
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x
The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed. 
Via Stocktwits
IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year
IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most subgroups. 
Via Benzinga
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
What's going on in today's after hours session
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
 
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Nasdaq Dips Over 2%; US Construction Spending Falls In July
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024
IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024
IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.